1 / 11

By: Reuven Sandyk

Speech Impairment in Parkinson’s Disease is Improved by Transcranial Application of Electromagnetic Fields. By: Reuven Sandyk. Parkinson’s Disease. Frequently associated with speech disturbance Affects 50-70% of patients An even greater percentage in advanced stages of disease.

chad
Télécharger la présentation

By: Reuven Sandyk

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Speech Impairment in Parkinson’s Disease is Improved by Transcranial Application of Electromagnetic Fields By: Reuven Sandyk

  2. Parkinson’s Disease • Frequently associated with speech disturbance • Affects 50-70% of patients • An even greater percentage in advanced stages of disease

  3. Parkinsonian Speech Impairment • Monotonous pitch • Slow rate • Decrease in volume (hypophonia) • Symptoms generally worse when patient is tired or anxious

  4. In mid to advanced stages • Phonemes are less articulated • Produces a hypokinetic dysarthria (stuttering) • Festinating speech • Dysfluency may become worse as disease progresses

  5. Hypothesis • Treatment with weak electromagnetic fields (EMFs) applied transcranially

  6. Case Report • 52 year old radiologist • Freezing of gate, increased difficulties with hypophonia and with articulation • Mental depression, chronic insomnia • Anxiety and autonomic symptoms • Hyperkinetic dysarthria-particulaly severe during periods of mental stress • Started on serotonergic medication one month before treatment started

  7. Treatment • Four years, one treatment session each week • Treatment session • Patient continued to take serotonergic and antiParkinsonian medications

  8. Results • 80-90% improvement in speech • Impact of treatment is best the day after • Effect of treatment lasts 5-6 days • Continues to experience “on-off” fluctuations • Dramatic improvement in cognitive functions • Speech impairment was one of first symptoms to reappear

  9. Discussion • Stuttering observed in young children • Acquired stuttering is rarely observed in adults • Transient stuttering-left hemispheric lesions • Acquired stuttering-bilateral cerebral lesions • Prefrontal lobe, caudate-putamen, limbic system

  10. Many symptoms associated with decreased levels of serotonin • SSRIs may improve speech impairment • Mechanisms by which EMFs improved speech impairment • Synaptic level • Synergistic interaction

  11. Conclusion Transcranial applications of EMFs may provide a novel, nonpharmacologic approach to the management of speech impairment associated with Parkinsonism

More Related